ClinicalTrials.gg
TerminatedNCT05722522Updated Mar 24, 2026Results posted

Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

A Phase 3 interventional study of Secukinumab and Placebo in Rotator Cuff Tendinopathy, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Project discontinued to prioritize other key programs in portfolio

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Tendinopathy with a site in United States — 15 open to participants now, 17 under way, none of them phase 3. Tendinopathy · United States.

Enrollment
49th of 89
33 · median 40
Started
2023
with 9 others
Phase 3
7 of 99
none open now
Registered
74th of 99
by date
Lead sponsor
4 of 99
Novartis Pharmaceuticals

Among the 99 studies in Tendinopathy with a site in United States, this one is the 49th largest by enrollment of the 89 interventional ones that give a count, is one of 10 that started in 2023, is one of 7 in phase 3, and was the 74th registered.

Tendinopathy

397 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

15 of the 99 studies in Tendinopathy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Tendinopathy studies recruiting now, 17 (36%) set no upper age limit and 23 (49%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Tendinopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of the present study was to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in participants with moderate to severe rotator cuff tendinopathy (RCT), using a randomized, double-blind, placebo controlled, parallel group design to minimize bias.

Read the detailed description

This was a randomized, double-blind, placebo-controlled Phase III study, stratified by tear status (no tear/ partial tear) in participants with moderate to severe rotator cuff tendinopathy (RCT), experiencing active disease from at least 6 weeks to 6 months at baseline, and were refractory to standard of care (non-steroidal anti-inflammatory drug [NSAIDs] and course of physiotherapy) over a period of 8 weeks.

The study was terminated due to the project being discontinued in order to prioritize other key programs in the portfolio. Due to the early termination and small sample size, the analysis by tear status stratification was not performed.

The study duration was up to 32 weeks, consisting of a screening period lasting up to 8 weeks (inclusive of a mandatory 2-week run-in period), a 16-week treatment period with last dose administered at Week 12, and an 8-week safety follow-up period. The primary endpoint assessment was at Week 16, and the safety follow-up data collection was through to Week 24.

03

Conditions studied

  • Rotator Cuff Tendinopathy

Browse trials for

Keywords

  • Moderate to Severe Rotator Cuff Tendinopathy
  • Adult
  • Unilateral
  • Refractory to standard of care
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unilateral rotator cuff tendinopathy with ≥ 6 weeks to ≤ 6 months symptom duration at baseline.
  2. Nocturnal pain in shoulder on at least 3 out of 7 nights in the week prior to baseline or "positive painful arc test" on examination.
  3. Total WORC percentage score ≤ 40 at the screening and baseline visits.
  4. Average weekly (i.e., the average of the 7 scores taken once a day) numerical rating scale (NRS) pain score of ≥5 during the past 7 days prior to the baseline visit.
  5. to standard of care: non-steroidal anti-inflammatory drug (NSAIDs) course as per local standard practice (if not intolerant or ) and a course of physiotherapy over a period of 8 weeks.
  6. Participant agreed to remain on stable NSAID dosage regimen (if not intolerant or having contraindications; NSAID dose was permitted to be reduced, but not increased above dose established at run-in) and physiotherapy regimen from run-in period until End of Study (EOS).
  7. Presence of tendinopathy in the affected shoulder on a centrally read MRI (Magnetic Resonance Imaging), with the following conditions: with no tear or partial tear (maximum 50% tendon thickness; anteroposterior (AP) length maximum 10 mm)

Exclusion criteria

Exclusion Criteria:

  1. Rheumatological and non-rheumatological inflammatory diseases, including but not limited to polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), axial spondyloarthritis (AS: ankylosing spondylitis, nr-axSpA: non-radiographic axial spondyloarthritis), psoriasis (PsO), and rheumatoid arthritis (RA); fibromyalgia or severe pain disorder unrelated to the target shoulder; gout; and systemic lupus erythematosus.
  2. Rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies positive at screening.
  3. Oral, intramuscular or intravenous (i.v.) treatment within the last 12 weeks prior to randomization, or presence of any condition that might require intermittent corticosteroid use.
  4. Lack of compliance with adhering to NSAID (unless intolerant or ) and physiotherapy regimen during run-in period.
  5. Positive painful arc test result in contralateral shoulder
  6. Inability or unwillingness to undergo MRI of the shoulder (e.g., participants with pacemakers, or metal fragments/foreign objects in the body that were not compatible with performing an MRI) to fulfill eligibility criteria (unless centrally read MRI images acquired within 3 months of baseline could be provided and the quality of images was deemed sufficient).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Participants received secukinumab 300 mg at randomization (baseline visit) and Weeks 1, 2, 3, 4, 8, and 12.

    Drug: Secukinumab

  • Placebo comparator
    Placebo

    Participants received placebo at randomization (baseline visit) and Weeks 1, 2, 3, 4, 8, and 12.

    Drug: Placebo

Interventions

  • 2 X secukinumab 150 mg / 1 mL as solution for subcutaneous (s.c.) injection

    Also known as: AIN457

  • DrugPlacebo

    2 X placebo / 1 mL as solution for s.c. injection

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16

    The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

    Time frame: At Week 16

Secondary outcomes

  1. Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form (SF) Upper Extremity Score

    PROMIS-SF Upper Extremity measures self-reported capability of physical function. Participants were asked a series of 7 questions rating their ability to perform a range of physical activities related to daily life that would be impacted by shoulder function. Each response was scored from 1 (unable to do) to 5 (without any difficulty). The responses for the 7 questions were added to the total raw score ranging from 7 (worst) to 35 (best) and converted to a T-score with a range from 16.3 (worst outcome) to 58.2 (best outcome), which was used for the analysis. Therefore, the theoretical range for the value for change from baseline for converted T-scores was between -41.9 to 41.9. A positive change from baseline indicated a better outcome.

    Time frame: At Week 16

  2. Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 16

    The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

    Time frame: At Week 16

  3. Percentage of Participants Who Achieved an Improvement (Increase) of at Least 50 Points From Baseline in the WORC Total Score

    The WORC is a patient-reported outcome tool, uniquely developed for rotator cuff conditions. The WORC is self-administered and consists of 21 items divided into five domains: physical symptoms, sport/recreation, work function, lifestyle function, and emotional function. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

    Time frame: At Week 16

  4. Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 24

    The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

    Time frame: At Week 24

  5. Change From Baseline in WORC PSD Score at Week 24

    The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

    Time frame: At Week 24

  6. Secukinumab Serum Concentrations

    Pharmacokinetic parameters (measures of treatment exposure) were evaluated in all participants, with moderate to severe RCT, treated with secukinumab 300 mg s.c.

    Time frame: Day 1 and Weeks 4 and 16

  7. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), by Maximum Severity

    Severity: Mild - usually transient in nature and generally not interfering with normal activities; Moderate - sufficiently discomforting to interfere with normal activities; Severe - prevents normal activities.

    Time frame: Up to Week 24

  8. Percentage of Participants With Clinically Significant Changes in Laboratory Parameters

    Laboratory parameters included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, albumin, amylase, calcium, creatinine, bilirubin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, urate, and urea nitrogen.

    Time frame: Up to Week 24

  9. Percentage of Participants With Clinically Significant Changes in Vital Signs

    Vital signs included sitting systolic blood pressure, sitting diastolic blood pressure, and sitting pulse rate.

    Time frame: Up to Week 24

  10. Percentage of Participants With Binding and Neutralizing Anti-drug Antibodies

    Time frame: At Day 1 and Week 16

07

Results

Posted Dec 2, 2025

Participant flow

Participant flow — Overall Study
MilestoneSecukinumabPlacebo
Started1716
Completed1715
Not completed01
Withdrew: Adverse event01

Outcome measures

PrimaryChange From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16

The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

Time frame:
At Week 16
Reported as:
Mean · score on a scale
Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 16
score on a scaleSecukinumabPlacebo
Change From Baseline in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) Score at Week 1645.89 ± 25.49038.40 ± 29.908
SecondaryChange From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form (SF) Upper Extremity Score

PROMIS-SF Upper Extremity measures self-reported capability of physical function. Participants were asked a series of 7 questions rating their ability to perform a range of physical activities related to daily life that would be impacted by shoulder function. Each response was scored from 1 (unable to do) to 5 (without any difficulty). The responses for the 7 questions were added to the total raw score ranging from 7 (worst) to 35 (best) and converted to a T-score with a range from 16.3 (worst outcome) to 58.2 (best outcome), which was used for the analysis. Therefore, the theoretical range for the value for change from baseline for converted T-scores was between -41.9 to 41.9. A positive change from baseline indicated a better outcome.

Time frame:
At Week 16
Reported as:
Mean · score on a scale
Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form (SF) Upper Extremity Score
score on a scaleSecukinumabPlacebo
Change From Baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) - Short Form (SF) Upper Extremity Score13.86 ± 10.53513.78 ± 11.098
SecondaryPercentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 16

The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 16
percentage of participantsSecukinumabPlacebo
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 1652.953.3
SecondaryPercentage of Participants Who Achieved an Improvement (Increase) of at Least 50 Points From Baseline in the WORC Total Score

The WORC is a patient-reported outcome tool, uniquely developed for rotator cuff conditions. The WORC is self-administered and consists of 21 items divided into five domains: physical symptoms, sport/recreation, work function, lifestyle function, and emotional function. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 50 Points From Baseline in the WORC Total Score
percentage of participantsSecukinumabPlacebo
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 50 Points From Baseline in the WORC Total Score64.743.8
SecondaryPercentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 24

The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 24
percentage of participantsSecukinumabPlacebo
Percentage of Participants Who Achieved an Improvement (Increase) of at Least 40 Points From Baseline in the WORC PSD Score at Week 2466.761.5
SecondaryChange From Baseline in WORC PSD Score at Week 24

The WORC PSD is a sub-domain of the WORC Patient-Reported Outcome (PRO) and comprises 6 questions that capture the key symptoms experienced by participants with rotator cuff tendinopathy (RCT) relating to pain, weakness, stiffness, and mechanical symptoms. The raw score was converted to a scale of 0 to 100, where 0 represents the most symptomatic score, and 100 represents no symptoms.

Time frame:
At Week 24
Reported as:
Mean · score on a scale
Change From Baseline in WORC PSD Score at Week 24
score on a scaleSecukinumabPlacebo
Change From Baseline in WORC PSD Score at Week 2451.19 ± 26.66443.67 ± 34.661
SecondarySecukinumab Serum Concentrations

Pharmacokinetic parameters (measures of treatment exposure) were evaluated in all participants, with moderate to severe RCT, treated with secukinumab 300 mg s.c.

Time frame:
Day 1 and Weeks 4 and 16
Reported as:
Mean · μg/mL
Secukinumab Serum Concentrations
μg/mLSecukinumab
Day 10.00 ± 0.00
Week 489.8 ± 20.1
Week 1637.0 ± 14.3
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs), by Maximum Severity

Severity: Mild - usually transient in nature and generally not interfering with normal activities; Moderate - sufficiently discomforting to interfere with normal activities; Severe - prevents normal activities.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), by Maximum Severity
percentage of participantsSecukinumabPlacebo
Mild29.418.8
Moderate17.60
Severe06.3
SecondaryPercentage of Participants With Clinically Significant Changes in Laboratory Parameters

Laboratory parameters included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, albumin, amylase, calcium, creatinine, bilirubin, glucose, lactate dehydrogenase, lipase, magnesium, phosphate, potassium, sodium, urate, and urea nitrogen.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Changes in Laboratory Parameters
percentage of participantsSecukinumabPlacebo
Percentage of Participants With Clinically Significant Changes in Laboratory Parameters00
SecondaryPercentage of Participants With Clinically Significant Changes in Vital Signs

Vital signs included sitting systolic blood pressure, sitting diastolic blood pressure, and sitting pulse rate.

Time frame:
Up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Changes in Vital Signs
percentage of participantsSecukinumabPlacebo
Percentage of Participants With Clinically Significant Changes in Vital Signs00
SecondaryPercentage of Participants With Binding and Neutralizing Anti-drug Antibodies
Time frame:
At Day 1 and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Binding and Neutralizing Anti-drug Antibodies
percentage of participantsSecukinumabPlacebo
Day 100
Week 1600

Adverse events

Collected over Adverse events were reported up to a maximum duration of 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab0/17 (0%)0/17 (0%)8/17 (47.1%)
Placebo0/16 (0%)1/16 (6.3%)3/16 (18.8%)
Most frequent serious events
Most frequent serious events
EventSecukinumabPlacebo
Colitis ischaemicGastrointestinal disorders0/171/16
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSecukinumabPlacebo
Joint range of motion decreasedMusculoskeletal and connective tissue disorders1/172/16
ArthralgiaMusculoskeletal and connective tissue disorders0/171/16
Tendon disorderMusculoskeletal and connective tissue disorders0/171/16
ParaesthesiaNervous system disorders0/171/16
PruritusSkin and subcutaneous tissue disorders0/171/16
LeukocytosisBlood and lymphatic system disorders1/170/16
Gingival bleedingGastrointestinal disorders1/170/16
NauseaGastrointestinal disorders1/170/16
PyrexiaGeneral disorders1/170/16
Hepatic cystHepatobiliary disorders1/170/16

Baseline characteristics

The randomized set included all participants who were randomized.

Age, Continuous
Age, Continuous(years)SecukinumabPlaceboTotal
Mean49.6 ± 10.6647.4 ± 10.1248.5 ± 10.30
Age, Customized
Age, Customized(participants)SecukinumabPlaceboTotal
18 - < 25 years112
25 - < 45 years448
45 - <= 65 years121123
Sex: Female, Male
Sex: Female, Male(Participants)SecukinumabPlaceboTotal
Female141024
Male369
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)SecukinumabPlaceboTotal
White151429
Asian123
American Indian or Alaska Native101
08

Study locations

15 sites
  • Millennium Clinical Trials
    Westlake Village, California 91361, United States
  • Healthy Life Research
    Miami, Florida 33184, United States
  • IRIS Research and Development
    Plantation, Florida 33324, United States
  • Precision Clinical Research LLC
    Sunrise, Florida 33351, United States
  • West Clinical Research
    Morehead City, North Carolina 28557, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Novartis Investigative Site
    San Miguel Tucuman, Tucumán Province 4000, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1114AAP, Argentina
  • Novartis Investigative Site
    San Miguel de Tucumán, 4000, Argentina
  • Novartis Investigative Site
    Sofia, 1336, Bulgaria
  • Novartis Investigative Site
    Québec, Quebec G1V 3M7, Canada
  • Novartis Investigative Site
    Brno, Czech Republic 66250, Czechia
  • Novartis Investigative Site
    Kolín, 280 02, Czechia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88300, Malaysia
  • Novartis Investigative Site
    Ponte de Lima, 4990-041, Portugal
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Oct 2024, 14 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2023
First posted
Feb 10, 2023
StartActual
Aug 10, 2023
Primary completionActual
Oct 17, 2024
CompletionActual
Dec 13, 2024
Results first posted
Dec 2, 2025
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05722522
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Aug 10, 2023
Primary completion
Oct 17, 2024
Completion
Dec 13, 2024
Results posted
Dec 2, 2025
Last update
Mar 24, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion